



## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/086,912	02/28/2002	Robert D.P. Hei	163.1440USU1	1677
23552 7:	590 08/20/2004		EXAM	INER
	& GOULD PC		PUTTLITZ	, KARL J
P.O. BOX 2903 MINNEAPOLI	3 IS, MN 55402-0903		ART UNIT	PAPER NUMBER
	,		1621	
			DATE MAILED: 08/20/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

•
2
_
0
v

Status

### Office Action Summary

Application No.	Applicant(s)	
10/086,912	HEI ET AL.	
Examiner	Art Unit	
Karl J. Puttlitz	1621	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address -- Period for Reply

# A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Otatas		
1)⊠ Resp	onsive to communication(s) filed	l on <u>28 July 2004</u> .
2a)∐ This a	action is <b>FINAL</b> . 2b	b)⊠ This action is non-final.
3) Since	this application is in condition for	or allowance except for formal matters, prosecution as to the merits is
close	d in accordance with the practice	e under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.
Disposition of	Claims	
4)⊠ Claim	(s) <u>1,2 and 4-29</u> is/are pending i	in the application.
4a) O	the above claim(s) <u>9-29</u> is/are v	withdrawn from consideration.
5) Claim	(s) is/are allowed.	
6)⊠ Claim	(s) <u>1, 2 and 4-8</u> is/are rejected.	
7)☐ Claim	(s) is/are objected to.	
8)☐ Claim	(s) are subject to restricti	ion and/or election requirement.
Application Pa	pers	
9)☐ The s	pecification is objected to by the	Examiner.

•	cement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). ath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.
•	35 U.S.C. § 119
12)∏ Ackno	wledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a)∐ All	b) Some * c) None of:
1.	Certified copies of the priority documents have been received.
2.	Certified copies of the priority documents have been received in Application No
3. 🗌	Copies of the certified copies of the priority documents have been received in this National Stage
	application from the International Bureau (PCT Rule 17.2(a)).

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

\* See the attached detailed Office action for a list of the certified copies not received.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Attachment(s)	
1) Notice of References Cited (PTO-892)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)	

4) Interview Summary (PTO-413)
Paper No(s)/Mail Date
5) Notice of Informal Patent Application (PTO-152)
6) Other:

Patent and	Trademark	Office

Paper No(s)/Mail Date \_\_\_\_

#### **DETAILED ACTION**

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114.

Applicant's submission filed on June 14, 2004 has been entered.

#### Claim Rejections - 35 USC § 112

Claims 1, 2 and 4-8 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for the specific peroxycarboxylic acids of the formula represented, for example, on page 8 of the specification does not reasonably provide enablement for all peroxycarboxylic acids. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make the invention commensurate in scope with these claims.

"The standard for determining whether the specification meets the enablement requirement [in accordance with the statute] was cast in the Supreme Court decision of *Mineral Separation v. Hyde*, 242 U.S. 261, 270 (1916) which postured the question: is the experimentation needed to practice the invention undue or unreasonable? That standard is still the one to be applied. *In re Wands*, 858 F.2d 731, 737, 8 USPQ2d 1400, 1404 (Fed. Cir. 1988).

Accordingly, even though the statute does not use the term "undue"

experimentation," it has been interpreted to require that the claimed invention be enabled so that any person skilled in the art can make and use the invention without undue experimentation. In re Wands, 858 F.2d at 737, 8 USPQ2d at 1404 (Fed. Cir. 1988). See also United States v. Telectronics, Inc., 857 F.2d 778, 785, 8 USPQ2d 1217, 1223 (Fed. Cir. 1988) ("The test of enablement is whether one reasonably skilled in the art could make or use the invention from the disclosures in the patent coupled with information known in the art without undue experimentation."). A patent need not teach, and preferably omits, what is well known in the art. In re Buchner, 929 F.2d 660, 661, 18 USPQ2d 1331, 1332 (Fed. Cir. 1991); Hybritech, Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 1384, 231 USPQ 81, 94 (Fed. Cir. 1986), cert. denied, 480 U.S. 947 (1987); and Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co., 730 F.2d 1452. 1463, 221 USPQ 481, 489 (Fed. Cir. 1984). Determining enablement is a question of law based on underlying factual findings. In re Vaeck, 947 F.2d 488, 495, 20 USPQ2d 1438, 1444 (Fed. Cir. 1991); Atlas Powder Co. v. E.I. du Pont de Nemours & Co., 750 F.2d 1569, 1576, 224 USPQ 409, 413 (Fed. Cir. 1984)." See M.P.E.P. § 2164.

In the instant case the claims cover a stabilized ester peroxycarboxylic acid composition comprising: an ester peroxcarboxylic acid compound and a C2 or higher alcohol being effective to stabilize the ester-peroxvcarboxvlic acid without an additional stabilizer.

Based on the above standards, the disclosure must contained sufficient information to enable one skilled in the pertinent art to use this invention without

Art Unit: 1621

undue experimentation. See M.P.E.P. 2164.01. Given the scope of the claims, it does not.

Specifically, the claims broadly recite: an ester peroxcarboxylic acid compound and a C2 or higher alcohol being effective to stabilize the ester-peroxvcarboxvlic acid without an additional stabilizer. The specification and the examples do not provide sufficient disclosure that would provide one of ordinary skill guidance to practice the invention, given the infinite amount of possible permutations of the claimed an ester peroxcarboxylic acid compound. In this regard, the disclosure does teach those of ordinary skill how to select appropriate co- an ester peroxcarboxylic acid compound, where the instant specification only describes a single formula. M.P.E.P. § 2164.06(b) citing "In *In re Vaeck*, 947 F.2d 488, 495, 20 USPQ2d 1438, 1444 (Fed. Cir. 1991), [where the court pointed to a] "limited disclosure by appellants of ...particular cyanobacterial genera operative in the claimed invention...." The claims at issue were not limited to any particular genus or species of cyanobacteria and the specification mentioned nine genera and the working examples employed one species of cyanobacteria."

Moreover, the specification and the examples do not provide sufficient disclosure that would provide one of ordinary skill guidance to practice the invention without an additional stabilizer. Given the state of the art, the specification does not teach those of ordinary skill how to practice the invention without an additional stabilizer.

The examiner understands that there is no requirement that the specification disclose every possible embodiment if there is sufficient guidance

Art Unit: 1621

given by knowledge in the art (See M.P.E.P. § 2164.05(a) "[t]he specification need not disclose what is well-known to those skilled in the art and preferably omits that which is well-known to those skilled and already available to the public. *In re Buchner*, 929 F.2d 660, 661, 18 USPQ2d 1331, 1332 (Fed. Cir. 1991); *Hybritech, Inc. v. Monoclonal Antibodies, Inc.*, 802 F.2d 1367, 1384, 231 USPQ 81, 94 (Fed. Cir. 1986), *cert. denied*, 480 U.S. 947 (1987); and *Lindemann Maschinenfabrik GMBH v. American Hoist & Derrick Co.*, 730 F.2d 1452, 1463, 221 USPQ 481, 489 (Fed. Cir. 1984).").

However, the instant case goes beyond what is known in the art, because the specification does not offer any guidance on how one of ordinary skill would go about practicing the invention for recovery of every claimed an ester peroxcarboxylic acid compound.

Applicant is reminded of the heightened enablement for chemical inventions. Specifically, the amount of guidance or direction needed to enable the invention is inversely related to the amount of knowledge in the state of the art as well as the predictability in the art. *In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). The "amount of guidance or direction" refers to that information in the application, as originally filed, that teaches exactly how to make or use the invention. The more that is known in the prior art about the nature of the invention, how to make, and how to use the invention, and the more predictable the art is, the less information needs to be explicitly stated in the specification. In contrast, if little is known in the prior art about the nature of the invention and the art is unpredictable, the specification would need more detail

Art Unit: 1621

as to how to make and use the invention in order to be enabling. [I]n the field of chemistry generally, there may be times when the well-known unpredictability of chemical reactions will alone be enough to create a reasonable doubt as to the accuracy of a particular broad statement put forward as enabling support for a claim. This will especially be the case where the statement is, on its face, contrary to generally accepted scientific principles. Most often, additional factors, such as the teachings in pertinent references, will be available to substantiate any doubts that the asserted scope of objective enablement is in fact commensurate with the scope of protection sought and to support any demands based thereon for proof. [Footnote omitted.]

Here, the requirement for enablement is not met since the claims go far beyond the enabling disclosure. Base on the forgoing claims 1, 2 and 4-8 are *prima facie*, non-enabled for their full scope.

## Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1, 2 and 4-8 rejected under 35 U.S.C. 103(a) as being unpatentable over WO 213.

Art Unit: 1621

The claims invention, as amended, is drawn to a stabilized ester peroxycarboxylic acid composition comprising: an ester peroxcarboxylic acid compound about 0.5 wt% to about 80 wt % C2 or higher alcohol; the C2 or higher alcohol being suitable for use in food products, for cleaning or sanitizing food processing equipment or materials, for use in a health-care environment or a combination thereof, C2 or higher alcohol being effective to stabilize the ester-peroxycarboxylic acid without an additional stabilizer and maintain at least about 30 % of antimicrobial activity of the composition for at least about 3 months.

WO 213 suggests the claimed composition within the meaning of § 103. Specifically, the claimed composition is suggested by Example 1, comprising esters of peracids from a starting material of ethanol. The reference also teaches that up to 10 % wt of the ethanol is residual in the final composition. See page 6, lines 1-4.

Specifcally, Example 1 teaches that a solution containing 14,04 g glutaric acid, 9,79 g ethanol, 17,65 g concentrated hydrogen peroxide (85,5% wt), 1 g concentrated sulphuric acid, 57,52 g demineralised water, 0,1 g p-hydroxy benzoic acid, 0,17 g of 1-hydroxyethane-1, 1-diphosphonic acid (Briquest ADPA 60A) was prepared with stirring, and allowed to reach equilibrium The molar ratio of ester peracid to monocarboxylic peroxycarboxylic acid found in the system was 1:8, measured by HPLC.

The difference between WO 213 and the claimed inventions is that WO 213 does not teach the invention with particularity so as to amount to anticipation (See M.P.E.P. § 2131: "[t]he identical invention must be shown in as complete

detail as is contained in the ... claim." *Richardson v. Suzuki Motor Co.*, 868 F.2d 1226, 1236, 9 USPQ2d 1913, 1920 (Fed. Cir. 1989). The elements must be arranged as required by the claim, but this is not an *ipsissimis verbis* test, i.e., identity of terminology is not required. *In re Bond*, 910 F.2d 831, 15 USPQ2d 1566 (Fed. Cir. 1990).). However, based on the above, WO 213 teaches the elements of the claimed invention with sufficient guidance, particularity, and with a reasonable expectation of success, that the invention would be *prima facie* obvious to one of ordinary skill (the prior art reference teaches or suggests all the claim limitations with a reasonable expectation of success. See M.P.E.P. § 2143).

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karl J. Puttlitz whose telephone number is (571) 272-0645. The examiner can normally be reached on Monday-Friday (alternate).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Johann Richter can be reached on (571) 272-0646.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Karl J. Puttlitz Assistant Examiner

Johann R. Richter, Ph.D., Esq. Supervisory Patent Examiner

Biotechnology and Organic Chemistry

Art Unit 1621 (571) 272-0646